Atypical Hemolytic Uremic Syndrome (aHUS)

Also known as: Atypical Hemolytic Uraemic Syndrome / Atypical Hemolytic-Uremic Syndrome / Atypical Hemolytic Uremic Syndrome / Hemolytic-Uremic Syndrome, Atypical / Hemolytic Uremic Syndrome, Atypical / Atypical hemolytic uremic syndrome (disorder) / Atypical haemolytic uraemic syndrome / AHUS

DrugDrug NameDrug Description
DB01257EculizumabA recombinant humanized monoclonal antibody used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
DrugDrug NameTargetType
DB01257EculizumabComplement C5target
DrugDrug NamePhaseStatusCount
DB15011Avacopan2Terminated1
DB16121Cemdisiran2Withdrawn2
DB01257Eculizumab2Completed7
DB01257Eculizumab2Recruiting1
DB16128Crovalimab3Not Yet Recruiting1
DB16128Crovalimab3Recruiting1
DB16200Iptacopan3Not Yet Recruiting1
DB16418Narsoplimab3Recruiting1
DB11580Ravulizumab3Active Not Recruiting2
DB01257Eculizumab4Completed1
DB01257Eculizumab4Not Yet Recruiting1
DB01257EculizumabNot AvailableRecruiting1